Last reviewed · How we verify
NCT05909709
Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
Phase 1 trial testing Alocyte low dose in Facet Joints; Degeneration in 15 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Alimorad Farshchian |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 29 April 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Alocyte low dose — full drug profile →
- Alocyte medium dose — full drug profile →
- Alocyte high dose — full drug profile →
Conditions studied
- Facet Joints; Degeneration — all drugs for Facet Joints; Degeneration →
- Back Pain — all drugs for Back Pain →
- Facet Joint Pain — all drugs for Facet Joint Pain →
Sponsor
Alimorad Farshchian — full company profile →
Who can join
18 and older, any sex, with Facet Joints; Degeneration or Back Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05909709
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05909709 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alimorad Farshchian
- Last refreshed: 13 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909709.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing